Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Research & Development (2017 - 2025)

Historic Research & Development for Crinetics Pharmaceuticals (CRNX) over the last 9 years, with Q3 2025 value amounting to $90.5 million.

  • Crinetics Pharmaceuticals' Research & Development rose 4613.36% to $90.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $313.6 million, marking a year-over-year increase of 4307.2%. This contributed to the annual value of $240.2 million for FY2024, which is 4250.3% up from last year.
  • Crinetics Pharmaceuticals' Research & Development amounted to $90.5 million in Q3 2025, which was up 4613.36% from $80.3 million recorded in Q2 2025.
  • In the past 5 years, Crinetics Pharmaceuticals' Research & Development ranged from a high of $90.5 million in Q3 2025 and a low of $17.6 million during Q1 2021
  • Over the past 5 years, Crinetics Pharmaceuticals' median Research & Development value was $42.2 million (recorded in 2023), while the average stood at $47.2 million.
  • As far as peak fluctuations go, Crinetics Pharmaceuticals' Research & Development surged by 6066.88% in 2022, and later skyrocketed by 2317.02% in 2023.
  • Quarter analysis of 5 years shows Crinetics Pharmaceuticals' Research & Development stood at $24.6 million in 2021, then skyrocketed by 50.35% to $37.0 million in 2022, then rose by 23.22% to $45.6 million in 2023, then surged by 46.04% to $66.6 million in 2024, then soared by 35.9% to $90.5 million in 2025.
  • Its last three reported values are $90.5 million in Q3 2025, $80.3 million for Q2 2025, and $76.2 million during Q1 2025.